Member Info for iTradeShares

I think that Buxton Resources is in a very similar place to GGP in the early days.

They have Gervaise Heddle (head of GGP during drilling phase) as Chairman.

They have identified a large magnetic anomaly very similar to Havieron.

Thet are about to start initial drilling.

The target is much shallower than Havieron.

Potential mine is close to Telfer processing plant.

Buxton is well funded for drilling campaign.

Best place to find gold is near a gold mine.

High probability that it is Starlink. There are not many easy ways to get exposure to Starlink, & it is of course the number 1 SMIT holding.

Social media posting where?

Someone had to write the first post on B HODL.

DATs (Digital Asset Treasuries) are a very hot sector right now. But many of them have no underlying business model. They simply buy/hold digital assets an try to ape the Microstrategy model.

B HODL is different. They plan to use their bitcoin HODL to run nodes on the Lightning network. This will generate revenue from transactions on the Lightning network.

I have invested on the basis of this revenue generating model, but also because I want to see more people being able to use btc for payments, using the Lightning network. BTC needs to move beyond store of value to payments.

The business has some excellent UK btc leaders, and I am confident that they will be successful with B HODL.

Yup - loading up in modest bites so as to avoid spiking the price.

And a couple more hefty buys this morning.

I have been doing some financial analysis on the recent report and accounts.

The rate of margin improvement in the current and future years will indeed be very substantial.

Based on a modest assumption of 89,000 additional deployments during fiscal 2026, the average monthly revenue per unit deployed rises from £1.44 (fiscal 2025) to £2.27. I have assumed that all units installed will be to either USA or NFU Mutual, charged at £3.70 per month (equivalent to $5 monthly).

As a consequence, I estimate that the gross margin will rise from 3% in fiscal 2025 to 35% in the current year. In future years, as the proportion of units installed at £3.70 ($5) per month rises rapidly, gross margin will increase to circa 75%, even with increasingly large numbers of deployed units generating minimal gross margin during their first year.

Digging through the weeds in the accounts, there are some modest future growth rate assumptions (CAGR) which point towards rapid improvements in the bottom line.

Sales 54% p.a

Gross Margin 143% p.a

Administrative expenses 6% p.a

My overall conclusion is that on an annual run rate basis, we will indeed hit break even before March 31 2026. Of course the 2026 accounts will still not show break even for the current year, so we may have to continue to be patient, waiting for those not invested to realise what a relatively undiscovered gem Ondo is.

My gut feel is that we will follow the Ting deployment trajectory and reach 1 million deployed units within the next 3 to 4 years, with the business generating very substantial and stable dividend income for investors.

Vascular - thanks for posting this news. The restructuring could certainly be the reason for the delay on receiving launch information.

Hopefully we will get specific launch information soon, now that the new management structure has been implemented.

Good post Vascular. A lot more considered than many other posts this morning.

The company is not going to hassle the retail group for specific information just so that an RNS can be issued to pacify nervous investors. For the retail partner, sending the company precise details of the launch is not going to be high on their priority list.

I am happy to wait for the launch to happen. The key clue to the future of the company will be the initial consumer purchase levels.

For me this is a small high risk component in my portfolio, but if the initial sales data indicate strong consumer uptake, I will be substantially increasing my position. INC could generate very exciting returns.

Nice bounce in the price today. Some people anticipating good news?

2phevs - many thanks for all the information you are finding/sharing.

Lots of positive indicators!

Management very constrained in what they could say about the imminent launch at the AGM, but it does seem that everything is on track.

At today’s price a top up it is looking very tempting!

As I understand things, if projected current year volumes are achieved, the company will have positive cash flow and also be profitable.

There should be no need for any further cash raising, so earnings per share are likely to be very attractive.

For me the key is consumer purchases during the initial weeks instore. Will the POS materials and product demonstrators be able to communicate the product benefits effectively, and will potential consumers be prepared to spend their money.

Initial trial purchases are key. If the products work as anticipated, then word of mouth and repeat purchases should build a solid brand.

Volmer - I agree that more precise information on the amended plans would have been reassuring, but as you say INC can only publish what Marionnaud approve.

My interpretation of the news is that the retailer wants to ensure that there is adequate stock for the greatly enlarged European launch. In addition to prioritising stock for repeat orders in Europe, they may also feel it is beneficial to finalise their launch plans for Asia using the initial European sales data. For forecasting purposes it is always extremely useful to have some idea of the retail sales mix, so that by SKU production can be optimised.

They have not said that the launch is Europe only, so I would assume that based on their growing confidence in Skin + CELL, they are still keen to maximise their opportunity by launching soon in Asia.

The key will be monthly units shipped. Investors want to see all these insurer contracts converted into high deployment rates. News of additional contracts isn’t moving the needle, so it has to be shipment data.

Vascular - I agree that the weekly sales per store required to move 350,000 units by the end of March are extremely modest.

If retail rate of sale proves to be significantly higher, we could see volumes well ahead of 350,000 units. I would assume that the manufacturer will be planning to quickly respond to additional order demand. Marionnaud will certainly have sought reassurance that replacement stock will be available on a timely basis.

The first week or two in-store will reveal how high Skin + CELL is going to fly. Hopefully during the AGM we will get an indication of initial sales rates.

I see this announcement as an extremely positive development. The decision for an accelerated roll out by our retail partner is very encouraging.

Marionnaud will have been conducting product training with their in-store demonstrators in advance of the launch. Perhaps the feedback from the in-store demonstrators has encouraged the buyers to accelerate the roll out. It certainly suggests a high level of confidence in the products.

Adding many additional stores to the launch inevitably creates a short delay as extra merchandising materials will have to be produced and additional demonstrator training delivered.

I don’t mind waiting a little longer for the in-store launch, if it means much higher volumes in the next few months. If initial sales go as anticipated, the repeat orders will be very substantial.

On Telegram (prior to his rapid undignified exit) & here, Jigger was claiming to have very bad news wrt Nationwide roll out in US.

Clearly this very positive RNS shows there was no substance to his claims.

Jigger credibility = Zero.

Well said Mafee.

The posting history of pump & dump charlatans is always very revealing.

Looking back over Jiggered’s recent history there are c45 posts on Ondo, and c 10 on other companies. Only one non Ondo post in the last month.

CORO and HVO briefly featured, but then disappeared completely off his radar.

How many AIM investors only have an interest in one company? A company he describes as probably failing, but out of the ‘goodness of his heart’, he wants to warn people away from.

Hopefully this bluebottle will find an open window soon, and buzz off to irritate people elsewhere.

No Jiggered - in the world of small cap investing, nobody is more hated than someone who tries to ramp/deramp to meet their own personal agenda, using highly selective and misleading ‘analysis’.

If you think Ondo is potentially declining you have zero analytical skills.

Why don’t you move your manipulation attempts across to another share? Both here and on Telegraph you have been well and truly rumbled. Your attempts to influence the SP are completely ineffective, but annoying to other posters. It is a bit like having a blue bottle buzzing around the bedroom at night.